SP1 and breast cancer: Nalla et al. demonstrated that empagliflozin-induced miR-128-3p inhibits SP1 and PKM2 activity in hypoxic breast cancer cells, promotes CD44+/CD24 + differentiated cells, and reduces metastasis of breast cancer cells [57].